Welcome to our dedicated page for Biomx news (Ticker: PHGE), a resource for investors and traders seeking the latest updates and insights on Biomx stock.
BiomX Inc. (PHGE) generates frequent news flow as a clinical-stage company developing natural and engineered bacteriophage therapies targeting specific pathogenic bacteria. Company press releases and Form 8-K filings describe how BiomX advances phage cocktails and personalized phage treatments for chronic conditions, including cystic fibrosis-related lung infections and diabetic foot disease. News coverage often centers on clinical trial progress, regulatory feedback, financing transactions and strategic updates that can influence the outlook for PHGE stock.
A major theme in BiomX news is the development of its phage product candidates. For BX004, a fixed multi-phage cocktail for cystic fibrosis patients with chronic Pseudomonas aeruginosa infections, the company has reported Phase 1b/2a data, FDA Fast Track and Orphan Drug designations, initiation of a Phase 2b trial, an FDA clinical hold related to a third-party nebulizer device, and ultimately the discontinuation of the Phase 2b study after internal review and Data Monitoring Committee feedback. Separate updates detail European enrollment, FDA correspondence on potential Phase 3 pathways, and safety reviews.
News items also highlight BiomX’s diabetic foot programs. The company has announced statistically significant positive topline Phase 2 results for BX211 in diabetic foot osteomyelitis and subsequent FDA feedback supporting the development pathway for BX011, a next-generation fixed multi-phage cocktail targeting Staphylococcus aureus in diabetic foot infections. Releases describe the rationale for prioritizing DFI, the incorporation of proprietary phages, and the role of non-dilutive funding from U.S. Defense Health Agency and Department of Navy-related sources.
Investors following PHGE can also expect updates on corporate and financial events, such as reverse stock split decisions, private placements of Series Y Convertible Preferred Stock and warrants, lease terminations at subsidiaries, and cost-cutting measures including workforce reductions. Together, these disclosures provide a detailed, evolving picture of BiomX’s clinical pipeline, regulatory interactions, capital structure and strategic alternatives. Bookmark this page to review new PHGE press releases, trial milestones and SEC-reported events as they are published.
BiomX (NYSE American: PHGE) will host a conference call on May 11, 2022, at 8:00 a.m. EDT to report first quarter 2022 financial results and provide business updates. BiomX is a clinical-stage microbiome company that focuses on developing natural and engineered phage therapies to combat chronic diseases, including cystic fibrosis and colorectal cancer. Interested parties can participate via a dedicated dial-in or through a live audio webcast available on the company’s website.
BiomX (NYSE: PHGE) reported its financial results for Q4 and the full year 2021, revealing a cash position of $63.1 million, up from $57.1 million in 2020. The company anticipates major clinical data readouts in 2022 for its cystic fibrosis (BX004) and atopic dermatitis (BX005) therapies. BiomX’s current cash runway supports operations through 2023, with potential for extension to mid-2024 via venture debt. The net loss for 2021 stood at $36.2 million, marking an increase from $30.1 million in 2020. A conference call is scheduled for today at 8:00 am ET.
BiomX Inc. (NYSE American: PHGE) has announced a conference call scheduled for March 30, 2022, at 8:00 a.m. EDT to discuss its fourth quarter and full year 2021 financial results along with business updates. The company specializes in developing natural and engineered phage therapies targeting bacteria linked to chronic diseases like cystic fibrosis and colorectal cancer. Investors can access the live webcast via biomx.com.
BiomX (NYSE American: PHGE) has announced that CEO Jonathan Solomon will present at three notable conferences in 2022. These include the Aegis Virtual Conference on February 24, the Chardan 4th Annual Microbiome Medicines Summit on March 1, and the Oppenheimer & Co. 32nd Annual Healthcare Conference on March 17. The presentations will highlight the company's development of innovative phage therapies targeting pathogenic bacteria related to various chronic diseases. Live webcasts will be available on BiomX's website.
BiomX (AMEX: PHGE) has announced a $5 million funding from the Cystic Fibrosis Foundation to support its Phase 1b/2a study of BX004, targeting chronic respiratory infections in cystic fibrosis patients. The funding will be provided in two tranches: an initial $3 million received in December 2021 and a potential additional $2 million upon completion of patient dosing. The study aims to assess the therapy's safety and efficacy, with results expected in 2022.
BiomX Inc. (PHGE), a clinical-stage microbiome company, announced its participation in two upcoming healthcare events: the Jefferies London Healthcare Conference from November 18-19, 2021 and the 2021 Phage Futures Congress Europe on November 23-24, 2021. At the Jefferies conference, an on-demand session will be presented by Jonathan Solomon, available from November 18. The Phage Futures Congress will feature a presentation titled “Nebulized Bacteriophage Therapy” by Myriam Golembo, Ph.D. on November 23. Webcasts will be accessible via the company's website.
BiomX (PHGE) announced a strategic shift to focus on its cystic fibrosis and atopic dermatitis programs, aiming for proof-of-concept data in 2022. The company has extended its cash runway to the end of 2023, supported by FDA clearance for its Phase 1b/2a trial in cystic fibrosis. BiomX will discontinue its acne program and postpone developments in inflammatory bowel disease and colorectal cancer.
As of September 30, 2021, BiomX reported a cash balance of $68.3 million and a net loss of $10 million for Q3 2021.
BiomX Inc. (NYSE American: PHGE) is set to hold a conference call on November 15, 2021, at 8:00 a.m. EDT to discuss third quarter 2021 financial results and provide business updates. The live audio webcast can be accessed through the company's website.
BiomX is a clinical-stage microbiome company focusing on novel phage therapies targeting pathogenic bacteria, impacting various chronic diseases including inflammatory bowel disease and colorectal cancer.
BiomX announced results from its Phase 2 clinical study of BX001, a topical treatment for acne. The study, involving 140 women with mild-to-moderate acne, met safety and tolerability endpoints with no adverse events reported. Statistically significant improvements were observed in skin appearance metrics, including inflammatory lesion counts (48.3% reduction, p0.0001) and non-inflammatory lesions (36.3% reduction, p<0.0001). However, no meaningful efficacy difference was noted compared to the vehicle. Subject satisfaction indicated preference for BX001 in reducing redness and improving skin feel.
BiomX (NYSE: PHGE) has entered a licensing agreement with Maruho Co. Ltd., granting Maruho the right of first offer for BX005, a product targeting atopic dermatitis, set to begin after Phase 1/2 trial results in 2022. Additionally, Maruho will invest $3 million in BiomX, supporting the ongoing study. BX005 aims to combat Staphylococcus aureus to improve skin microbiome health. BiomX’s innovative phage-based approach highlights its potential in addressing dermatological issues. The announcement marks a significant collaboration in one of the largest dermatology markets.